- $1.51bn
- $1.76bn
- $2.53bn
Hims & Hers rises after plan to sell Eli Lilly's weight loss drug on its platform
Hims & Hers to sell Lilly's Zepbound on its telehealth platform (updated)
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
U.S. RESEARCH ROUNDUP- Array Technologies, Nextracker, Sutro Biopharma
U.S. STOCKS ON THE MOVE-CoreCivic, Teladoc, Dynavax
Teladoc, LifeMD tie up with Lilly's pharmacy partner to offer Zepbound (updated)
Teladoc climbs on Lilly tie up to offer Zepbound
Brief: Teladoc Health Adds GLP-1 Self-Pay Option To Comprehensive Weight Care
Telehealth firms Teladoc, LifeMD tie up with Eli Lilly's pharmacy partner to offer Zepbound
U.S. STOCKS ON THE MOVE-Apple, Zevra Therapeutics, Agilent Technologies
U.S. STOCKS ON THE MOVE-Amazon, Novavax, Ecovyst
Street View: Mental health unit to weigh on Teladoc
U.S. STOCKS ON THE MOVE-Urban Outfitters, Vistra, Bath & Body Works
U.S. STOCKS ON THE MOVE-Nvidia, Moderna, Goldman Sachs
Teladoc down on wider loss, disappointing revenue forecast
Teladoc Health Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Teladoc Health Q4 Adjusted EBITDA USD 74.835 Million Vs. IBES Estimate USD 82.2 Million
Brief: Blue Orca Capital Says We Are Short Teladoc Health- X Post
Brief: Teladoc Health to Acquire Catapult Health, Advancing Integrated Care Strategy